Eddy D M, Sanders L E, Eddy J F
Surv Ophthalmol. 1983 Nov-Dec;28(3):194-205. doi: 10.1016/0039-6257(83)90097-8.
This paper estimates the value of performing Schiotz tonometry to detect glaucoma in an asymptomatic patient. About 9% of adults over 40 will be found on a single Schiotz tonometry test to have elevated intraocular pressure (IOP). On work-up, about 1 out of 50 of these individuals with high IOP will be found to have glaucoma. Tonometry, however, will miss about half of all patients with glaucoma because they do not have elevated IOPs at the time of the test. Pilocarpine or epinephrine are the most commonly used drugs to treat the disease, but they are not always effective in lowering a patient's IOP or in stopping the progression of field defects. From the available evidence it does not appear that earlier diagnosis makes a substantial difference in the patient's outcome. If all individuals over 40 years of age in a city of 1,000,000 were screened, the total cost of finding and treating about 484 people with chronic simple glaucoma would be on the order of $4,944,866 or about $13,000 per patient potentially benefited. Screening with tonometry does not appear to be warranted.
本文评估了对无症状患者进行 Schiotz 眼压测量以检测青光眼的价值。在单次 Schiotz 眼压测量测试中,约9% 的40岁以上成年人会被发现眼压升高(IOP)。在进一步检查中,这些眼压高的个体中约每50人有1人会被发现患有青光眼。然而,眼压测量会漏诊约一半的青光眼患者,因为他们在测试时眼压并未升高。毛果芸香碱或肾上腺素是治疗该病最常用的药物,但它们在降低患者眼压或阻止视野缺损进展方面并不总是有效。从现有证据来看,早期诊断似乎并未对患者的预后产生实质性影响。如果对一个拥有100万人口城市中所有40岁以上的人进行筛查,发现并治疗约484例慢性单纯性青光眼患者的总成本约为4944866美元,即每位潜在受益患者约13000美元。用眼压测量进行筛查似乎没有必要。